Publications by authors named "Scott Lunin"

Claim this Profile
U
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Jeff P Sharman, Danielle M Brander, Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, Scott D Lunin

Lancet Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Guillermo Garcia-Manero, Gail Roboz, Katherine Walsh, Hagop Kantarjian, Ellen Ritchie, Scott Lunin

Lancet Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Ian W Flinn, Carole B Miller, Kirit M Ardeshna, Scott Tetreault, Sarit E Assouline, Scott D Lunin

J Clin Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Scott Lunin

Blood· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Gail J Roboz, Hagop M Kantarjian, Karen W L Yee, Patricia L Kropf, Casey L O'Connell, Scott D Lunin

Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia.
William Donnellan, Jesus G Berdeja, Diana Shipley, Edward R Arrowsmith, David Wright, Scott Lunin

Oncologist· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
John D Hainsworth, F Anthony Greco, Eric L Raefsky, Dana S Thompson, Scott Lunin

Clin Lymphoma Myeloma Leuk· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
John D Hainsworth, David R Spigel, Howard A Burris, Tiffanie M Markus, Dianna Shipley, Scott Lunin

Cancer· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Srdan Verstovsek, Scott Lunin, Hagop Kantarjian, Taghi Manshouri, Stefan Faderl

Leuk Res· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis